#1 Clinical Trials Search in Europe

Garetosmab

Garetosmab is an experimental drug currently being studied in clinical trials for its potential to treat rare bone disorders and obesity. These trials aim to assess the safety, tolerability, and effectiveness of garetosmab in patients with conditions such as Fibrodysplasia Ossificans Progressiva (FOP) and obesity. The studies are investigating how garetosmab affects bone formation, heterotopic ossification, and body composition when used alone or in combination with other medications.

Table of Contents

What is Garetosmab?

Garetosmab, also known as REGN2477, is an experimental drug being studied for its potential to treat rare bone disorders and, more recently, as part of a combination therapy for obesity[1][2][3]. It is a type of medication called a monoclonal antibody, which means it’s a laboratory-created protein designed to target specific substances in the body.

Conditions Treated by Garetosmab

Garetosmab is primarily being investigated for the treatment of two main conditions:

  • Fibrodysplasia Ossificans Progressiva (FOP): This is a rare and serious genetic disorder where the body’s soft tissues (such as muscles, tendons, and ligaments) gradually turn into bone. This process is called heterotopic ossification (HO). FOP can severely limit a person’s movement and cause significant pain and disability[1][2].
  • Obesity: More recently, garetosmab is being studied as part of a combination therapy with other drugs for treating obesity[3].

How Garetosmab Works

Garetosmab works by targeting a protein in the body called Activin A. In conditions like FOP, Activin A is believed to play a role in the abnormal bone formation process. By binding to and blocking Activin A, garetosmab aims to prevent or reduce the formation of extra bone tissue in soft tissues[1][2].

In the context of obesity treatment, the exact mechanism is still being studied, but it’s thought that blocking Activin A might help with fat loss and body composition changes when combined with other medications[3].

Clinical Trials and Research

Garetosmab is currently being studied in several clinical trials:

  • A study in Japan is assessing its safety and effectiveness in adult patients with FOP[1].
  • A larger, global Phase 3 study is evaluating garetosmab against a placebo in adults with FOP[2].
  • A study is investigating garetosmab in combination with other drugs (trevogrumab and semaglutide) for weight loss and fat loss in adults with obesity[3].

These trials are looking at various aspects, including:

  • How well garetosmab prevents new bone formation in FOP patients
  • Its effect on FOP flare-ups (episodes of painful swelling that often lead to new bone formation)
  • Changes in body weight and fat mass when used as part of an obesity treatment
  • The drug’s safety profile and potential side effects
  • How the body processes the drug (pharmacokinetics)
  • Whether the body develops antibodies against the drug

How Garetosmab is Administered

In the clinical trials, garetosmab is administered intravenously (IV), meaning it’s given directly into a vein. The treatment is typically given every four weeks (Q4W)[1][2]. In the obesity study, it’s being tested in combination with other drugs that are given subcutaneously (under the skin)[3].

Potential Side Effects and Safety

As garetosmab is still in the research phase, its full safety profile is not yet established. The clinical trials are closely monitoring for any side effects, which researchers call “treatment-emergent adverse events” (TEAEs). These could range from mild to severe. Patients in the trials are being watched for any unexpected reactions, especially those that might be related to changes in bone metabolism or the immune system[1][2][3].

Future Prospects and Ongoing Research

The research on garetosmab is ongoing, and it’s not yet approved for general use. The results of these clinical trials will help determine if garetosmab is safe and effective enough to become an approved treatment for FOP or as part of a combination therapy for obesity. If successful, it could provide a much-needed treatment option for people with FOP, a condition that currently has no approved treatments. For obesity, it could potentially offer a new approach when combined with existing treatments[1][2][3].

Aspect Details
Drug Name Garetosmab (REGN2477)
Primary Conditions Studied Fibrodysplasia Ossificans Progressiva (FOP), Obesity
Administration Method Intravenous (IV) every 4 weeks, some studies exploring subcutaneous (SC) administration
Key Objectives Assess safety, tolerability, and efficacy in reducing new bone formation and flare-ups in FOP; Evaluate effects on body composition and weight loss in obesity when combined with other medications
Main Outcome Measures Number of new heterotopic ossification (HO) lesions, incidence of adverse events, changes in body weight and fat mass
Secondary Assessments Changes in joint function, pulmonary function, quality of life measures, pharmacokinetics, and immunogenicity
Imaging Techniques Used Computed Tomography (CT), Positron Emission Tomography (PET)
Combination Therapies Studied with semaglutide for obesity treatment; some trials explore combination with trevogrumab

FAQ

  • What is Garetosmab? Garetosmab, also known as REGN2477, is an experimental drug being studied for its potential to treat rare bone disorders and obesity. It is a monoclonal antibody that targets a specific protein in the body.
  • What conditions is Garetosmab being studied for? Garetosmab is primarily being studied for Fibrodysplasia Ossificans Progressiva (FOP), a rare genetic disorder that causes abnormal bone growth. It is also being investigated for its potential in treating obesity when combined with other medications.
  • How is Garetosmab administered in clinical trials? In the clinical trials, Garetosmab is typically administered intravenously (IV) every four weeks. Some studies are also exploring subcutaneous (under the skin) administration.
  • What are the main goals of the Garetosmab clinical trials? The main goals of these trials are to assess the safety, tolerability, and effectiveness of Garetosmab. Researchers are looking at its effects on new bone formation, flare-ups in FOP patients, and changes in body composition in obesity studies.
  • Are there any known side effects of Garetosmab? As Garetosmab is still in clinical trials, all potential side effects are not yet known. The studies are carefully monitoring for any adverse events to establish the safety profile of the drug.

Ongoing Clinical Trials on Garetosmab

  • Study on the Safety and Effectiveness of Garetosmab for Adults with Fibrodysplasia Ossificans Progressiva

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Finland France Italy The Netherlands Poland Spain

Glossary

  • Fibrodysplasia Ossificans Progressiva (FOP): A rare genetic disorder characterized by the gradual replacement of muscles, tendons, and ligaments with bone, leading to severely restricted movement.
  • Heterotopic Ossification (HO): The formation of bone tissue outside of the skeleton, which is a key feature of FOP and can cause significant disability.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Garetosmab is a monoclonal antibody.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Subcutaneous (SC): A method of administering medication under the skin.
  • Flare-up: In FOP, a flare-up is an episode of inflammation that can lead to new bone formation.
  • Computed Tomography (CT): A medical imaging technique that uses X-rays to create detailed images of the body.
  • Positron Emission Tomography (PET): A type of imaging test that uses a radioactive tracer to visualize how your tissues and organs are functioning.
  • Anti-drug Antibodies (ADA): Antibodies produced by the immune system against a therapeutic drug, which can potentially reduce its effectiveness.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References